Premium
Tripeptide and hexapeptide topical as adjunct to nonablative fractional resurfacing for photodamage: A randomized split‐face trial
Author(s) -
Wang Jordan V.,
Christman Mitalee P.,
Feng Hao,
Ferzli Georgina,
Jeon Hana,
Geronemus Roy G.
Publication year - 2020
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.13795
Subject(s) - tripeptide , medicine , randomized controlled trial , tolerability , clinical trial , surgery , tissue remodeling , dermatology , adverse effect , chemistry , inflammation , peptide , biochemistry
Background Topical adjuncts have been investigated to improve clinical outcomes associated with laser resurfacing for photodamage and cutaneous aging. One such product is a tripeptide/hexapeptide serum, which has been shown to increase dermal collagen and elastin as well as improve postprocedural recovery following treatments. Aims A randomized, blinded, split‐face, comparative trial was performed to assess the utility of a tripeptide/hexapeptide serum as a peri‐procedural adjunct to nonablative fractional laser resurfacing. Patients/Methods A total of 20 subjects were enrolled. Each hemiface was randomized to either tripeptide/hexapeptide serum or bland moisturizer for twice daily application starting 14 days prior to first laser treatment and continuing until 60 days after. All subjects received 2 treatments to entire face approximately 1 month apart with 1927 nm thulium nonablative fractional laser. Clinical measures and immediate postprocedural recovery were assessed. Results For each hemiface, scores improved for all measures, including global photodamage, lentigines, pores, radiance, texture, and tone at 30 and 60 days. The tripeptide/hexapeptide serum had greater improvements for all measures at both time points, except for radiance at 60 days, which was equal. In cases where clinical ratings differed between sides, tripeptide/hexapeptide serum more frequently had the superior outcome. Overall, subjects were satisfied with tripeptide/hexapeptide serum. No significant adverse events were observed. Conclusion Addition of tripeptide/hexapeptide serum as a peri‐procedural adjunct to nonablative fractional laser resurfacing improved various clinical measures of photodamage and cutaneous aging and the immediate postprocedural recovery. The tripeptide/hexapeptide serum was demonstrated to be safe, well‐tolerated, and well‐liked by subjects.